One dose of adjuvant 8 Gray postoperative radiotherapy for Merkel cell carcinoma excised with narrow margins
Low toxicity and comparable efficacy to conventional radiotherapy.
Huynh ET, Ch'en PY, Hippe DS, Fan X, Goff PH, Biese K, Fu A, Menon A, Harikrishnan N, Lachance K, Wallner K, Panjwani N, Parvathaneni U, Tseng YD, Akaike T, Zaba LC, Nghiem P
Journal of the American Academy of DermatologyIn the feed 20 Jul 2026, published online 20 Jul 2026, issue 2026 Jul 20, added to PubMed 20 Jul 2026
Topics: Skin cancer & tumorsOther tumors & cystsSurgery & Mohs
Abstract
BACKGROUNDMerkel cell carcinoma (MCC) recurs in 17% to 30% of patients with stage I to II disease, with local recurrence rates between 2% and 27%. Per established guidelines, conventional postoperative radiotherapy (cPORT; ∼50 Gray across 25 fractions) should be considered for localized MCC when risk factors are present. cPORT can be morbid and logistically challenging. Single-fraction radiotherapy (SFRT) of 8 Gray has utility and low toxicity for palliation but remains underexplored postoperatively.
OBJECTIVEEvaluate postoperative SFRT for stage I to II MCC, compared to observation and cPORT.
METHODSLocal recurrences were assessed for observation (n = 108 patients), cPORT (n = 156), or SFRT (n = 43) groups.
RESULTSObservation patients had fewer per-patient risk factors (mean: 1.2 vs 1.6 for SFRT [P = .020] and 1.6 for cPORT [P = .001]). Despite this, 3-year local control was better for cPORT (97.4%; P < .001) and SFRT (100%; P = .012) groups than observation (91.0%), particularly in patients with narrow surgical margins (≤1 cm). Adverse events occurred in 21% of SFRT patients (all grade 1).
LIMITATIONSSingle-center retrospective study.
CONCLUSIONSThe SFRT group experienced improved local control relative to observation and had comparable local control to the cPORT group. For early-stage narrowly excised MCC, SFRT is feasible, well tolerated, and warrants exploration in a prospective multicenter study.
Abstract from PubMed
PMID 42476365 · DOI 10.1016/j.jaad.2026.07.041